# 117-hr-9687: Medical Innovation Act of 2022

117-hr-9687, Medical Innovation Act of 2022, is a 117th Congress bill sponsored by Sen. Welch, Peter [D-VT] (D-VT); status Referred to the House Committee on Energy and Commerce. (as of 2025-11-18).

- Canonical: https://policyrisk.com/legislation/117-hr-9687
- As of: 2025-11-18
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Bill: 117-hr-9687
- Congress: 117
- Title: Medical Innovation Act of 2022
- Status: Referred to the House Committee on Energy and Commerce.
- Introduced: 2022-12-22
- Sponsor: Sen. Welch, Peter [D-VT] (D-VT)
- Cosponsors: 0
- Policy area: Health
- Touches household money: no
- Last recorded action: 2025-11-18

## Summary

Medical Innovation Act of 2022 This bill requires certain drug manufacturers to make payments to fund research supported by the Food and Drug Administration (FDA) and the National Institutes of Health (NIH). A drug manufacturer with over $1 billion in net income in a fiscal year that has entered into a relevant settlement agreement regarding specified violations must pay 0.75%-1.5% of its net income to the Department of Health and Human Services for each of its covered blockbuster drugs. A covered blockbuster drug is a drug that has at least $1 billion in net sales in a year and was developed, in whole or in part, through federal investments in medical research. Payments are divided between the FDA and the NIH in proportion to the discretionary funding of those agencies, excluding FDA user fees. Payments are not disbursed if appropriations for the FDA or the NIH are lower than in the prior fiscal year. Priorities for payments must include advancing regulatory science for medical products and research related to diseases that disproportionately account for federal health care spending. A covered blockbuster drug for which a manufacturer has not made a required payment is considered misbranded and subject to prohibitions on introducing or receiving misbranded drugs in interstate commerce.

## Related bills

- 117-hr-1667: Dr. Lorna Breen Health Care Provider Protection Act
- 117-hr-1448: PAWS for Veterans Therapy Act
- 117-hr-3537: Accelerating Access to Critical Therapies for ALS Act
- 117-hr-3525: Commission To Study the Potential Creation of a National Museum of Asian Pacific American History and Culture Act
- 117-hr-7132: Safe Connections Act of 2022
- 117-hr-7791: Access to Baby Formula Act of 2022

## Sources
- [117-hr-9687 on Congress.gov](https://www.congress.gov/bill/117th-congress/house-bill/9687)

## Related
- [117-hr-1667: Dr. Lorna Breen Health Care Provider Protection Act](https://policyrisk.com/legislation/117-hr-1667)
- [117-hr-1448: PAWS for Veterans Therapy Act](https://policyrisk.com/legislation/117-hr-1448)
- [117-hr-3537: Accelerating Access to Critical Therapies for ALS Act](https://policyrisk.com/legislation/117-hr-3537)
- [117-hr-3525: Commission To Study the Potential Creation of a National Museum of Asian Pacifi…](https://policyrisk.com/legislation/117-hr-3525)
- [117-hr-7132: Safe Connections Act of 2022](https://policyrisk.com/legislation/117-hr-7132)
- [117-hr-7791: Access to Baby Formula Act of 2022](https://policyrisk.com/legislation/117-hr-7791)
- [All bills in Congress](https://policyrisk.com/legislation)

Source: PRIA, https://policyrisk.com/legislation/117-hr-9687 (as of 2025-11-18).